Thesis
Post-restructuring neuroscience vaccine platform with two Phase 2 readouts converging on same runway before cash runs out in Q4 2027
After a 30% workforce cut in late 2025, AC Immune is a neuroscience vaccine company running parallel bets on alpha-synuclein immunotherapy in early Parkinson's and anti-amyloid immunotherapy in prodromal Alzheimer's, both pre-efficacy. The thesis resolves on whether ACI-7104.056 Phase 2 Part 1 data shows disease modification and ACI-24 AD3 Abeta PET data shows meaningful plaque reduction, since either hit could anchor a partnership before Q4 2027 cash exhaustion. The unusual risk is that both programs rely on biomarker surrogate endpoints, not clinical outcomes, leaving approvability genuinely unresolved past these readouts.
Focus
ACI-7104 VacSYn Phase 2 Part 1 final data readout
H2 2026
Bull
A positive outcome would show robust, durable anti-alpha-synuclein antibody responses sustained to week 104, alongside favorable trends in CSF alpha-synuclein, NfL, DaT-SPECT, and UPDRS III scores that signal disease modification in early PD. This would substantiate regulatory engagement for Part 2, potentially attract a partnership or non-dilutive funding, and validate the vaccine platform as a differentiated approach ahead of the cash cliff.
Bear
The most likely failure modes are insufficient or waning immunogenicity at week 104, absence of meaningful biomarker signals on functional or imaging endpoints (DaT-SPECT, UPDRS III), or emergent safety findings that complicate the benefit-risk profile. Any of these outcomes would undermine the case for Part 2 initiation and leave the company with a weakened lead asset and limited runway to pivot.
Unlock the full thesis for ACIU.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.